Imperative Care’s Zoom 88 Support Large Distal Platform OK’ed

Imperative Care, a company developing tech for those affected by stroke and other ischemic diseases, has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Zoom 88 large distal platform (LDP) support, expanding the Zoom 88 LDP.
 
Zoom 88 support bolsters Imperative Care’s 0.88” intracranial access catheter portfolio, which already has the Zoom 88 LDP and ZOOM RDL access platform. Further, the Zoom Stroke Solution has four vessel-matching Zoom aspiration catheters with an angled tip to enhance clot ingestion. The Zoom pump with Zoom POD provides sterile-field clot capture, as well.
 
The newly cleared Zoom 88 support has a new engineered support profile to maintain the capability of 0.88” intracranial access with further stability. That way, physicians can have more control over thrombectomy procedures in more patients, according to the company.
 
“Zoom 88 Support was purposefully designed to meet the needs of more patients and deliver on the feedback we’ve received from physicians. Zoom 88 Support provides the same benefits of intracranial access found with Zoom 88 LDP, with the ability to treat more proximal or tandem occlusions,” Ariel Sutton, GM of Imperative Care’s Stroke business, told the press. “With the introduction of Zoom 88 Support, we continue to grow our patient-first portfolio to bring the benefits of large-bore intracranial access to more people.”
 
Imperative Care also successfully the first cases utilizing Zoom 88 Support. One case offered the 0.88” intracranial access from the femoral artery so the distal occlusion could be treated with a Zoom aspiration catheter, and so a stable platform to treat the proximal occlusion could be achieved. All of this brough about complete TICI 3 vascularization.
 
Imperative’s Zoom RDL radial access system for ischemic stroke treatment earned FDA 510(k) clearance in January of this year.